Products for Research Use Only

EFdA-TP (tetralithium)

CAT: 0804-HY-138561CSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-138561CSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
EFdA-TP tetralithium is a potent nucleoside reverse transcriptase (RT) inhibitor. EFdA-TP tetralithium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT) . EFdA-TP tetralithium inhibits HIV-1 RT with multiple mechanisms[1].
UNSPSC
12352005
Target
HIV; Reverse Transcriptase
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Purity
96.23
Solubility
H2O : ≥ 100 mg/mL
Smiles
O=[P](O[P](O[P](O[Li])(O[Li])=O)(O[Li])=O)(O[Li])OC[C@]1(O[C@@](C[C@@H]1O)([H])N2C3=NC(F)=NC(N)=C3N=C2)C#C
Molecular Formula
C12H11FLi4N5O12P3
Molecular Weight
556.93
References & Citations
[1]Eleftherios Michailidis, et al. 4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms. J Biol Chem. 2014 Aug 29;289 (35) :24533-48.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products